Literature DB >> 17427006

[FSME monitoring: monitoring of adverse events of tick-borne-encephalitis vaccines by selected paediatricians and general practitioners].

Robert Weinzettel1, Susanne Ertl, Karl Zwiauer.   

Abstract

The Institute for Vaccine-Safety of the Austrian Green Cross, the so-called "Institut für Impfsicherheit des Osterreichischen Grünen Kreuzes", promoted a postmarketing sentinel study referring to the safety of tick-borne-encephalitis vaccines in spring 2002. Five-hundred selected paediatricians and general practitioners took part and generated data on 25,905 administered doses. They reported on 107/25,907 (0.413 %) local and systemic adverse reactions. The leading side-effect was fever, besides other adverse reactions corresponding to those known in the literature. The age-group most often affected was that of toddlers and infants. Monitoring with the help of selected paediatricians and general practitioners, carried out alongside the routine obligatory procedures of monitoring, proved to be a valid instrument for detecting vaccine adverse events of tick-borne-encephalitis vaccines.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17427006     DOI: 10.1007/s10354-007-0391-0

Source DB:  PubMed          Journal:  Wien Med Wochenschr        ISSN: 0043-5341


  6 in total

1.  History of TBE vaccines.

Authors:  P Noel Barrett; Susanne Schober-Bendixen; Hartmut J Ehrlich
Journal:  Vaccine       Date:  2003-04-01       Impact factor: 3.641

Review 2.  TBE vaccination and the Austrian experience.

Authors:  Christian Kunz
Journal:  Vaccine       Date:  2003-04-01       Impact factor: 3.641

3.  Antigen dependent adverse reactions and seroconversion of a tick-borne encephalitis vaccine in children.

Authors:  G Eder; H Kollaritsch
Journal:  Vaccine       Date:  2003-09-08       Impact factor: 3.641

4.  A tick-borne encephalitis vaccine without human serum albumin as stabilizer.

Authors:  Michael Bröker; Olaf Zent
Journal:  Vaccine       Date:  2005-09-30       Impact factor: 3.641

5.  Safety and immunogenicity of the modified adult tick-borne encephalitis vaccine FSME-IMMUN: results of two large phase 3 clinical studies.

Authors:  A Loew-Baselli; R Konior; B G Pavlova; S Fritsch; E Poellabauer; F Maritsch; P Harmacek; M Krammer; P N Barrett; H J Ehrlich
Journal:  Vaccine       Date:  2006-04-03       Impact factor: 3.641

6.  Tick-borne encephalitis: development of a paediatric vaccine. A controlled, randomized, double-blind and multicentre study.

Authors:  O E Girgsdies; G Rosenkranz
Journal:  Vaccine       Date:  1996-10       Impact factor: 3.641

  6 in total
  1 in total

Review 1.  [Tick-borne encephalitis].

Authors:  R Kaiser
Journal:  Nervenarzt       Date:  2016-06       Impact factor: 1.214

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.